{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:13:41Z","timestamp":1789244021838,"version":"build-2803163510"},"reference-count":16,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Toxicol"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:p>Tavaborole, a cyclized boronic acid, has been approved by the Food and Drug Administration for the topical treatment of toenail onychomycosis. This novel, low-molecular-weight pharmaceutical compound has broad-spectrum antifungal activity against dermatophytes, yeasts, and molds responsible for the disease. Tavaborole was tested in 2-year carcinogenicity studies in mice (once daily dermal administration) and rats (once daily by oral gavage) as part of the extensive nonclinical safety program. There was no evidence of tavaborole-related neoplasms observed in either study. Based on the data gathered from these 2 carcinogenicity studies, tavaborole is considered noncarcinogenic.<\/jats:p>","DOI":"10.1177\/1091581814545245","type":"journal-article","created":{"date-parts":[[2014,9,8]],"date-time":"2014-09-08T23:40:31Z","timestamp":1410219631000},"page":"419-427","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Tavaborole, a Novel Boron-Containing Small Molecule for the Topical Treatment of Onychomycosis, Is Noncarcinogenic in 2-Year Carcinogenicity Studies"],"prefix":"10.1177","volume":"33","author":[{"given":"Vic","family":"Ciaravino","sequence":"first","affiliation":[{"name":"Anacor Pharmaceuticals Inc, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Coronado","sequence":"additional","affiliation":[{"name":"Anacor Pharmaceuticals Inc, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Lanphear","sequence":"additional","affiliation":[{"name":"MPI Research, Inc, Mattawan, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Shaikh","sequence":"additional","affiliation":[{"name":"ITR Laboratories Canada Inc, Baie d\u2019Urfe, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Ruddock","sequence":"additional","affiliation":[{"name":"ITR Laboratories Canada Inc, Baie d\u2019Urfe, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Chanda","sequence":"additional","affiliation":[{"name":"Anacor Pharmaceuticals Inc, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,9,7]]},"reference":[{"key":"bibr1-1091581814545245","doi-asserted-by":"publisher","DOI":"10.1159\/000017990"},{"key":"bibr2-1091581814545245","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.2.157"},{"key":"bibr3-1091581814545245","doi-asserted-by":"publisher","DOI":"10.7547\/87507315-87-12-571"},{"key":"bibr4-1091581814545245","doi-asserted-by":"publisher","DOI":"10.7547\/87507315-87-12-565"},{"key":"bibr5-1091581814545245","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70484-0"},{"key":"bibr6-1091581814545245","unstructured":"Lamisil [package insert]; Novartis Pharmaceuticals Corporation. 2011."},{"key":"bibr7-1091581814545245","unstructured":"Sporanox [package insert]; Janssen. 2001."},{"key":"bibr8-1091581814545245","doi-asserted-by":"publisher","DOI":"10.1021\/jm0603724"},{"key":"bibr9-1091581814545245","doi-asserted-by":"publisher","DOI":"10.1126\/science.1142189"},{"key":"bibr10-1091581814545245","unstructured":"KERYDIN\n                      \n                        tm\n                      \n                      (tavaborole) topical solution, 5% [package insert]; Anacor Pharmaceuticals, Inc. 2014."},{"key":"bibr11-1091581814545245","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0022-3565(25)08751-8","volume":"82","author":"Draize JH","year":"1944","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr12-1091581814545245","first-page":"311","volume-title":"Monographs on the Long-Term and Short-Term Screening Assays for Carcinogens: A Critical Appraisal. IARC Monographs","author":"Peto R","year":"1980"},{"key":"bibr13-1091581814545245","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.68.2.478"},{"key":"bibr14-1091581814545245","doi-asserted-by":"publisher","DOI":"10.1039\/c0cs00131g"},{"key":"bibr15-1091581814545245","doi-asserted-by":"publisher","DOI":"10.1039\/c0md00119h"},{"key":"bibr16-1091581814545245","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200109000-00005"}],"container-title":["International Journal of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1091581814545245","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1091581814545245","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1091581814545245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:24:34Z","timestamp":1777458274000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1091581814545245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1177\/1091581814545245"],"URL":"https:\/\/doi.org\/10.1177\/1091581814545245","relation":{},"ISSN":["1091-5818","1092-874X"],"issn-type":[{"value":"1091-5818","type":"print"},{"value":"1092-874X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}